July 28, 2020
Chugai Pharmaceutical enjoyed higher profits on higher revenue in the first half of 2020 as exports of its major rheumatoid arthritis (RA) drug Actemra (tocilizumab) and hemophilia treatment Hemlibra (emicizumab) more than offset the impact of negative factors at home...read more